Ompekimig
Ompekimig is an immunoglobulin monoclonal antibody that targets IL-4, IL-13, IL-33. Ompekimig shows potential for use in immune-mediated inflammatory diseases such as asthma and atopic dermatitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2981477-39-6
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
immunoglobulin (L-kappa-H-gamma1(_L-VH-G1(CH1-h))_L-kappa)_( H-gamma1_L-kappa)
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-4 |
IL-13 |
IL-33 |
In Vitro
Ompekimig is an antibody against hIL-4, hIL-13, and hIL-33[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Fab-kappa_IgG1-kappa_disulfide
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 2981477-39-6
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Ompekimig
- 2981477-39-6
- Interleukin Related
- heavy chain amino acid sequences
- light chain amino acid sequences
- N-terminal glutaminyl cyclization
- fucosylated complex bi-antennary CHO-type N-glycosylation
- disulfide bridges
- post-translational modifications
- monoclonal antibody
- C-terminal lysine clipping
- N-terminal cyclization
- N-glycosylation
- Inhibitor
- inhibitor
- inhibit